References
- Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and α-interferon therapy. J Hepatol 1996; 25: 972–975
- Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107: 133–144
- Zeuzem S. Treatment of hepatitis C virus infection. Schweiz Rundsch Med Prax 2005; 94: 721–726
- Sagir A, Wettstein M, Heintges T, Haussinger D. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci 2002; 47: 652–653
- Medeiros BC, Seligman PA, Everson GT, Forman LM. Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavirin treatment for hepatitis C. J Clin Gastroenterol 2004; 38: 84–86
- Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, Rituximab. Am J Hematol 2005; 78: 138–141
- Sevastianos VA, Deutsch M, Dourakis SP, Manesis EK. Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol 2003; 98: 706–707
- Lambotte O, Gelu-Simeon M, Maigne G, Kotb R, Buffet C, Delfraissy JF, Goujard C. Pegylated interferon alpha-2a-associated life-threatening Evans’ syndrome in a patient with chronic hepatitis C. J Infect 2005; 51: 113–115
- Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999; 53: 242–254
- Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991; 78: 2619–2625
- Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002; 123: 1070–1083
- Ahn YS, Rocha R, Mylvaganam R, Garcia R, Duncan R, Harrington WJ. Long term danazol therapy in autoimmune thrombocytopenia, unmaintained remission and age-dependent response in women. Ann Intern Med 1989; 111: 723–729
- Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 24: 135–140
- Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 2000; 110: 98–103
- Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: Clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 2005; 129: 818–824
- Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, Sata M. Short term and two-step interferon therapy for chronic hepatitis C patients with low HCV RNA levels. Hepatol Res 2002; 22: 145–151
- Fried MW. Clinical application of hepatitis C virus genotyping and quantitation. Clin Liver Dis 1997; 1: 631–646
- Bozdayi G, Rota S, Verdi H, Derici U, Sindel S, Bali M, Basay T. The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution. Mikrobiyol Bul 2002; 36: 291–300
- Abacioglu YH, Davidson F, Tuncer S, Yap PL, Ustacelebi S, Yulug N, Simmonds P. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995; 2: 297–301